The reverse stock split proposal signals the company is at risk of delisting from Nasdaq due to low share price. If approved, the split could temporarily boost share price above minimum bid requirements but does not address fundamental business challenges. Monitor vote outcome and any subsequent Nasdaq compliance notices.
Price Chart
Executive Summary
Aprea Therapeutics filed a DEFA14A providing notice of its 2026 Annual Meeting, including proposals to elect three Class I directors, ratify EisnerAmper LLP as auditor, approve a reverse stock split (1:3 to 1:8), and hold advisory votes on executive compensation. The reverse stock split proposal is critical for maintaining Nasdaq listing compliance given the company's $10M market cap.
Key Financial Metrics
Key Facts
- Annual Meeting scheduled for June 16, 2026; vote deadline June 15, 2026
- Proposal 3 seeks approval for reverse stock split at ratio between 1:3 and 1:8, with exact ratio set by Board
- Proposal 6 allows adjournment to solicit additional proxies if insufficient votes for reverse split
- Board recommends FOR all proposals including reverse split
- Market cap is $10M, indicating potential Nasdaq listing compliance risk
Financial Impact
Reverse stock split at 1:3 to 1:8 ratio would proportionally reduce share count; no dollar amounts disclosed
Risk Factors
- Failure to approve reverse split could lead to Nasdaq delisting
- Reverse split may not resolve underlying business performance issues
- Low market cap ($10M) suggests limited liquidity and potential going concern risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001104659-26-052049 |
| Document: 0001104659-26-052049-index-headers.html | 0001104659-26-052049 |
| Document: 0001104659-26-052049-index.html | 0001104659-26-052049 |
| Document: 0001104659-26-052049.txt | 0001104659-26-052049 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 28, 2026 8w ago | 8-K | $0.8386 | awaiting T+60 | — | $0.5180 (−38.23%) |
Aug 12, 2026 10w ago | 8-K | $0.6830 | awaiting T+60 | — | $0.5180 (−24.16%) |
Aug 12, 2026 10w ago | Press Release | $0.6830 | awaiting T+60 | — | $0.5180 (−24.16%) |
May 13, 2026 23w ago | 8-K | $0.8800 $0.6503 | ▼ −26.10% | ▼ −30.54% | $0.5180 (−41.14%) |
May 13, 2026 23w ago | Press Release | $0.8800 $0.6503 | ▼ −26.10% | ▼ −30.54% | $0.5180 (−41.14%) |
Apr 30, 2026 25w ago | DEFA14A | $0.8000 $0.6247 | ▲ +21.91% | ▲ +25.02% | $0.5180 (+35.25%) |
Apr 22, 2026 26w ago | S-3 | $0.8840 $0.6690 | ▲ +24.32% | ▲ +29.34% | $0.5180 (+41.40%) |
Apr 21, 2026 26w ago | Press Release | $0.9070 $0.6900 | ▼ −23.93% | ▼ −30.82% | $0.5180 (−42.89%) |
Mar 31, 2026 29w ago | Insider Cluster | $0.7630 $0.7900 | ▲ +3.54% | ▼ −8.84% | $0.5180 (−32.11%) |
Mar 20, 2026 31w ago | EFFECT | $0.7620 $0.6990 | ▼ −8.27% | ▼ −22.69% | $0.5180 (−32.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers